Search Result

Results for "

CDK2-IN-4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (1) Apoptosis (6) Autophagy (2) CDK (14) CXCR (2) Cyclin G-associated Kinase (GAK) (1) EGFR (1) HIV (2) Ligands for Target Protein for PROTAC (1) LIM Kinase (LIMK) (1) PKC (2) PROTACs (2) Salt-inducible Kinase (SIK) (1) Wee1 (1)
By Research Areas:	Cancer (16) Inflammation/Immunology (2) Neurological Disease (2)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Natural
Products

Click Chemistry

Targets Recommended: Dan family AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117535

*CDK2-IN-4* 2 Publications Verification	CDK	Cancer
CDK2-IN-4 (compound 73) is a potent and selective *CDK2* inhibitor with an IC₅₀ of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC₅₀=86 uM) .

HY-10005

Flavopiridol Maximum Cited Publications 41 Publications Verification HMR-1275; Alvocidib; L86-8275	CDK Autophagy HIV Apoptosis	Cancer
Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC₅₀s of 30, 170, 100 nM, respectively.

HY-10006

Flavopiridol Hydrochloride Maximum Cited Publications 41 Publications Verification Alvocidib Hydrochloride; L86-8275 Hydrochloride; HMR-1275 Hydrochloride	CDK Autophagy HIV	Cancer
Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC₅₀s of 30, 170, 100 nM, respectively.

HY-50943

AT7519 Hydrochloride 10+ Cited Publications	CDK Apoptosis	Cancer
AT7519 Hydrochloride is a potent inhibitor of CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

HY-50940

AT7519 10+ Cited Publications AT7519M	CDK Apoptosis	Cancer
AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

HY-50940A

AT7519 TFA 10+ Cited Publications AT7519M TFA	CDK	Cancer
AT7519 (AT7519M) TFA as a potent inhibitor of CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

HY-114177

Ebvaciclib 2 Publications Verification PF-06873600	CDK	Cancer
PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with K_i values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity .

HY-156116

EGFR/CDK2-IN-4	EGFR CDK	Cancer
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor of EGFR and CDK-2 with IC₅₀s of 89.6 and 165.4 nM, respectively. EGFR/CDK2-IN-4 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-4 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC₅₀ of 2.74 μM .

HY-169910

*CDK2 degrader 4*	CDK	Cancer
CDK2 degrader 4 (compound 104) is a potent *CDK2* degrader. CDK2 degrader 4 has the potential for the research of cancer .

HY-151071

TMX-3013	CDK	Cancer
TMX-3013 is a CDKs inhibitor capable of inhibiting the activity of CDK1, *CDK2, CDK4*, CDK5, and CDK6, with IC₅₀ values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM, respectively. TMX-3013 can be utilized for synthesizing PROTACs that feature a polyethylene glycol (PEG) linker arm and Thalidomide (HY-14658) as the CRBN-recruiting arm .

HY-151069

TMX-2039	Ligands for Target Protein for PROTAC CDK	Cancer
TMX-2039 is a pan-CDK inhibitor for both cell cycle CDKs (CDK1, *CDK2, CDK4*, CDK5 and CDK6) and transcriptional CDKs (CDK7 and CDK9), with IC₅₀s of 2.6, 1.0, 52.1, 0.5, 35.0, 32.5 and 25 nM, respectively. TMX-2039 acts as a Ligands for Target Protein for PROTACs .

HY-18981

Decursin 1 Publications Verification (+)-DecursIN	PKC Apoptosis CXCR	Neurological Disease Inflammation/Immunology Cancer
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .

HY-111244

DCB-3503	Others	Others
DCB-3503 is a small molecule inhibitor of cell cycle progression, which has the activity of inducing G?/G? phase arrest and apoptosis in human hepatoma cells. DCB-3503 can inhibit the proliferation of human hepatoma cells, induce cell cycle arrest and apoptosis, and its mechanism is related to downregulating cyclin-dependent kinase (CDK) 2, CDK4 and CDK6, while activating PARP, caspase-3, caspase-9 and Bax, and downregulating Bcl-2.

HY-116204

SKLB70326	Others	Others
SKLB70326 is a small molecule inhibitor of cell cycle progression, which has the activity of inducing G?/G? phase arrest and apoptosis in human hepatoma cells. SKLB70326 can inhibit the proliferation of human hepatoma cells, induce cell cycle arrest and apoptosis, and its mechanism is related to downregulating cyclin-dependent kinase (CDK) 2, CDK4 and CDK6, while activating PARP, caspase-3, caspase-9 and Bax, and downregulating Bcl-2.

HY-18981R

Decursin (Standard)	PKC Apoptosis CXCR	Neurological Disease Inflammation/Immunology Cancer
Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities [4].

HY-148213

CDK2/4/6-IN-1	CDK	Cancer
CDK2/4/6-IN-1(example 29) is a *CDK2/4/6* inhibitor with IC₅₀ values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-162619

CDK9-IN-33	Apoptosis CDK	Cancer
CDK9-IN-33 (compound C35) is a potent, selective and orally active CDK9 inhibitor with IC₅₀ values of 17.44, 160, 316.30, 1771.00, >10000 nM for CDK9, CDK7, CDK2, CDK4, CDK6 respectively. CDK9-IN-33 induces apoptosis. CDK9-IN-33 decreases the protein expression of RPB1 CTD Ser2, RPB1, MCL1. CDK9-IN-33 shows anti-tumor activity .

HY-148065

FMF-06-098-1	PROTACs	Cancer
FMF-06-098-1 is a multitargeted depressant. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .

HY-148062

RSS0680	PROTACs CDK AAK1 Cyclin G-associated Kinase (GAK) Salt-inducible Kinase (SIK) LIM Kinase (LIMK) Wee1	Others
RSS0680 (Example 22) is a bifunctional compound targeted protein degradation of kinases. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used for research of disease or disorder mediated by aberrant kinase activity .(Pink: FLT3-IN-17 (HY-148070); Black: Linker (HY-W041970); Blue: E3 ligase Ligand (HY-112078))

Decursin 1 Publications Verification (+)-DecursIN	Structural Classification Classification of Application Fields Source classification Coumarins Phenylpropanoids Umbelliferae Plants Inflammation/Immunology Disease Research Fields Echinacea angustifolia DC.	PKC Apoptosis CXCR
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .

Decursin (Standard)	Structural Classification Source classification Coumarins Phenylpropanoids Umbelliferae Plants Echinacea angustifolia DC.	PKC Apoptosis CXCR
Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities [4].

Cat. No.	Product Name		Classification

HY-148213

CDK2/4/6-IN-1		Alkynes
CDK2/4/6-IN-1(example 29) is a *CDK2/4/6* inhibitor with IC₅₀ values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

CDK2-IN-4

Inhibitors & Agonists

NaturalProducts

Click Chemistry

Natural
Products